Comparative Physical and Pharmacologic Characteristics of Iodine-131 and Yttrium-90: Implications for Radioimmunotherapy for Patients with Non-Hodgkin's Lymphoma.

Radioimmunotherapy (RIT) is a promising new treatment option for patients with relapsed/refractory non-Hodgkin's lymphoma. Clinical trials have demonstrated that both iodine-131 ([SUP131]I) and yttrium-90 ([SUP90]Y) are suitable radionuclides for RIT. Iodine-131 and [SUP90]Y differ markedly in their physical properties including half-life, path length, type of energy emissions, intracellular stability, and the organs targeted by the free radionuclide. Both radionuclides can be safely administered in the outpatient setting under current Nuclear Regulatory Commission guidelines. Potential advantages of [SUP131]I for RIT include availability, stable chemistry, longer half-life, and an emission spectrum that allows for dosimetric studies and therapy with the same immunoconjugate. By contrast, [SUP90]Y has a longer path length and superior intracellular stability compared with [SUP131]I. Yttrium-90 may therefore be preferable to [SUP131]I for patients with bulky disease, poorly vascularized solid tumors, or when targeting internalized antigens. Although [SUP90]Y emits no gamma photon, dosimetry studies for [SUP90]Y RIT can be performed using a surrogate radionuclide such as indium-111. Both [SUP131]I- and [SUP90]Y-labeled anti-CD20 antibodies have demonstrated efficacy in treating relapsed/refractory non-Hodgkin's lymphoma. Further studies are needed, however, to determine if the differences in the pharmacology of [SUP131]I and [SUP90]Y are clinically relevant. [ABSTRACT FROM AUTHOR]

Copyright of Cancer Investigation is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)